Top Markets
Coin of the day
Vaxil Bio Ltd. Vaxil Bio Ltd.

Vaxil Bio Ltd.

VXL
株式のランク #39494
Vaxil Bio Ltd. is a biotechnology firm dedicated to discovering and developing... Vaxil Bio Ltd. is a biotechnology firm dedicated to discovering and developing innovative therapeutic agents. Its foundation lies in a unique signal peptide-based platform, which it leverages to address critical health challenges, specifically infectious diseases and various cancers. The company's primary therapeutic candidate, ImMucin, has successfully advanced through Phase I/II clinical trials as a potential treatment for multiple myeloma. Beyond ImMucin, Vaxil Bio is actively developing a vaccine/treatment for tuberculosis, as well as a vaccine targeting coronavirus (COVID-19). Strategic alliances bolster its research efforts; Vaxil Bio collaborates with The Tel Aviv Sourasky Medical Center on a research initiative to create a peptide-based COVID-19 vaccine. Furthermore, it holds a Cooperative Research and Development Agreement with the U.S. Army Medical Research Institute of Infectious Diseases to assess CorVax's efficacy in preventing COVID-19 in murine models. Established in 2006, the company's operations are based in Toronto, Canada.
株価
$0.1174299
最終同期: 2026-08-13
時価総額
$467.84K
変化(1日)
-8.57%
変化(1年)
1.38%
CA
取引 Vaxil Bio Ltd. (VXL)

カテゴリー

Vaxil Bio Ltd.(VXL)の発行済株式数
August 2026 時点の発行済株式数 0
Vaxil Bio Ltd. の最新の財務報告および株価によると、現在の発行済株式数は 0 です。August 2026 の終わりには、同社は 0 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
Vaxil Bio Ltd.(VXL)の発行済株式数の履歴(2026 ~ 2026)
各年末時点の発行済株式数
発行済株式数 変化
提供された日付のデータは十分ではありません。
類似企業や競合他社の発行済株式数
企業 発行済株式数
253.90M -
US
62.19M -
NL
- -
CH
- -
KR
0.00 -
BE